Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

LY3023414 × Tumor-Agnostic × 1 year × Clear all

Status

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 2 Gastrointestinal 2 Breast 2 Tumor-Agnostic 1 Myeloid 1 Lymphoid 1 Gynecologic 1 Genitourinary 1 CNS 1

Conditions

Interventions

pembrolizumab 52 Specimen Handling 29 Magnetic Resonance Spectroscopy 26 Biopsy 23 Nivolumab 20 Paclitaxel 19 Standard of Care 18 Blood Specimen Collection 17 atezolizumab 15 Bevacizumab 15 Surveys and Questionnaires 12 Fluorouracil 12 Cyclophosphamide 12 Carboplatin 12 Oxaliplatin 11 Radiotherapy 10 Leucovorin 10 Cisplatin 10 olaparib 9 Radiosurgery 9 Irinotecan 9 Ipilimumab 9 Interviews as Topic 9 Capecitabine 9 trastuzumab deruxtecan 8 Gemcitabine 8 Docetaxel 8 durvalumab 7 avelumab 7 Taxes 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡